Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
LCTX
Strong SellSinkerLineage Cell Therapeutics, Inc. · Healthcare · United States · $281M · Avg Vol: $905K/d
5
StockRankGet insider-trade alerts
Q
27
V
25
M
21
P/E (TTM)
—
ROE
-60.1%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.7M | 8.9M | 9.5M | 14.6M | -0.3% | 13.1M | 15.2M | 16.8M | 7.5% |
| EPS | -0.15 | -0.12 | -0.09 | -0.28 | — | -0.19 | — | — | — |
| Shares | 170.1M | 175.0M | 220.4M | 243.1M | +42.9% | 252.9M | — | — | — |
| Debt | 3.9M | 3.0M | 2.5M | 2.4M | -14.7% | 2.3M | — | — | — |
| Equity | 73.3M | 63.4M | 78.4M | 44.5M | -15.3% | — | — | — | — |
| Op CF | 1.1M | -28.6M | -23.1M | -18.9M | — | -23.8M | — | — | — |
| Inv CF | -46.2M | 46.4M | -2.3M | -13.5M | — | — | — | — | — |
| Fin CF | 1.6M | 6.4M | 35.9M | 26.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-8.1%
SMA 50SMA 200
Close
$1.02
RSI (14)
40.6
52W High
$2.09
From 52W High
0.5%
SCORE BREAKDOWN
Quality
27
ROIC
-26.5%26.2
ROE
-60.1%15.6
GP/Assets
-6.7%6.9
Op. Margin
-834.7%7.7
FCF/Assets
-21.7%19.7
Piotroski
431.0
Int. Cover
—N/A
D/E Ratio
0.04x73.8
Current Ratio
6.61x79.5
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-8.6x25.0
P/FCF
—N/A
P/B
4.5x32.6
P/S
20.9x15.7
Div Yield
—N/A
Momentum
21
52W High %
49%22.3
RS 6M
-52%12.0
SMA 50/200
0.78x13.9
EPS Rev 4W
-13.3%7.0
EPS Rev 12W
—N/A
EPS Improve
+46%52.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$281M
P/E (Forward)
-10.6x
Gross Margin
99.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LCTX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LCTX | Lineage Cell Therapeutics, Inc.(you) | $281M | 5 | Strong Sell |
| ALEC | Alector, Inc. | $261M | 5 | Strong Sell |
| NMRA | Neumora Therapeutics, Inc. | $261M | 5 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| GLSI | Greenwich LifeSciences, Inc. | $230M | 4 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| FHTX | Foghorn Therapeutics Inc. | $356M | 7 | Strong Sell |
| LYEL | Lyell Immunopharma, Inc. | $356M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%